May 13, 2026 | BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs

FDA approves Beqalzi (sonrotoclax) for mantle cell lymphoma — the first new BCL-2 inhibitor in a decade, directly challenging AbbVie's Venclexta franchise. Takeda slashes 4,500 jobs in a $1.26B restructuring; Lilly and Novo duel with new obesity maintenance data on the same day.Visit us a www.thepharmcloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, BeOne, Beqalzi, sonrotoclax, BCL-2 inhibitor, mantle cell lymphoma, AbbVie, Venclexta, Takeda, restructuring, layoffs, Eli Lilly, Novo Nordisk, obesity, GLP-1, Zepbound, Foundayo, Tessera Therapeutics, sickle cell disease, gene editing, FDA leadership, Makary, Assertio, Zydus, Pfizer, Hympavzi, hemophilia, Valneva, Galapagos, Lakefront Biotherapeutics, Merck KGaA, hantavirus, Replimune, Lilly, Merck, BMS, Gilead, Moderna